Psoriasis drug meets primary endpoints

|By:, SA News Editor

Pfizer's (PFE) Janus kinase inhibitor XELJANZ (tobacitinib), a twice-daily oral pill for the treatment of moderate-to-severe plaque psoriasis, meets its primary endpoints in two Phase 3 clinical trials, OPT Pivotal #1 and OPT Pivotal #2.

The primary efficacy endpoints were a statistically significant superiority over placebo at week 16 in the proportion of patients achieving a Physicians Global Assessment response of clear or almost clear and at least a 75% reduction in Psoriasis Area and Severity Index.

The company expects to submit a sNDA for the indication in early 2015.

The drug is currently approved for rheumatoid arthritis in cases where methotrexate does not work well.